Skip to main content

Advertisement

Figure 1 | Malaria Journal

Figure 1

From: The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea

Figure 1

Prevalence of mutations in pfmdr1 , pfcrt , pfdhfr and pfdhps in patient samples from Papua New Guinea. CQ, chloroquine; SP, sulphadoxine-pyrimethamine; pfmdr1, Plasmodium falciparum multidrug resistance gene 1; pfcrt, Plasmodium falciparum chloroquine resistance transporter; pfdhfr, Plasmodium falciparum dihydrofolate reductase; pfdhps, Plasmodium falciparum dihydropteroate synthase; no mutation was detected in any of the other SNP sites analysed (13/24 sites).

Back to article page